For informational purposes only — not investment advice

← Back to signals

AARD

Aardvark Therapeutics, Inc.

Research: Finviz ↗·Perplexity ↗

No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.

Days to cover (short int.)
1.0d↑+119.1%
as of 2026-10-30 · shares short vs 2026-09-30

News Summary

Negative

Aardvark secured FDA clinical hold removal for ARD-101 in October 2026, a modest positive, but the company faces significant headwinds from equivocal Phase 3 HERO trial data and cardiac safety signals that triggered multiple analyst downgrades. With cash runway through 2027 (~$60M), widening net losses ($19.2M in Q3, 18% above consensus), and a critical FDA meeting needed in Q1 2027 to chart the development path forward, the company remains in a precarious position dependent on trial redesign approval.

Red flags

  • •Net loss of $19.2M in Q3 2026 significantly exceeded analyst consensus (~$15.8M miss of ~21%)
  • •Equivocal Phase 3 HERO trial data for lead program ARD-101 cited by multiple analysts
  • •Cardiac safety signals in ARD-101 led to voluntary dosing pause (Feb 2026) and FDA clinical hold
  • •Four major analyst downgrades within 2 weeks (Raymond James, Oppenheimer, Wainwright, Stifel) with price target cuts of 50-67%
  • •Cash position declined 18% quarter-over-quarter to $60.3M with funding runway limited to 2027
  • •Development path for lead program remains uncertain pending Q1 2027 FDA meeting outcome
  • •R&D expenses increased 15% YoY while maintaining flat G&A, indicating elevated burn without revenue

Fund 13D/13G Filings (1)

Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).

FundForm∆ Shares% of ClassSince FilingFiledSrc
Citadel AdvisorsSC 13G/A—4.5%
-17.4% vs SPY
-20.6% abs
2026-11-16↗